Metrics to compare | 6461 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6461PeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.9x | 15.3x | −0.3x | |
PEG Ratio | 0.27 | 0.16 | 0.00 | |
Price/Book | 3.2x | 4.3x | 2.6x | |
Price / LTM Sales | 58.8x | 5.4x | 3.1x | |
Upside (Analyst Target) | - | 9.1% | 50.4% | |
Fair Value Upside | Unlock | −0.1% | 6.4% | Unlock |
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.